

KEVIN T. COLLINS, Partner

Kevin T. Collins represents companies in the life sciences, food, chemical and technology sectors. Clients seek his counsel in connection with SEC registered and privately placed equity and debt financings, mergers and acquisitions, strategic partnering and licensing transactions, corporate governance matters and securities law compliance.

Mr. Collins has led engagement teams on numerous transactions for companies in the following industries:

- Pharmaceuticals
- Biotechnology
- Medical Devices
- Food
- Chemicals
- Technology

He has significant experience advising clients on the following matters:

- Initial Public Offerings (IPOs)
- Follow-on Public Offerings
- Mergers
- Acquisitions and Sales of Businesses and Assets
- Strategic Partnerships
- Collaboration Agreements
- Corporate Governance

Mr. Collins is co-chair of the Corporate Practice, chair of the Lifesciences and Healthcare Practice and a member of the Mergers and Acquisitions and Securities Practices. He also serves as a member of the firm's Management Committee. In addition, Mr. Collins was named a *Law360* MVP for capital markets in 2016 and has been recognized for mergers and acquisitions by *New York Super Lawyers* from 2014 to 2017.

REPRESENTATIVE MATTERS

- Snyder's-Lance Inc. in its \$6.1 billion sale to Campbell Soup Company;
- Swiss-based Lonza Group Ltd. in its acquisition of all outstanding shares of Capsugel SA, for a purchase price of \$5.5 billion;
- Swiss-based Lonza Group Ltd. in a \$2.3 billion rights offering and in an \$865 million accelerated bookbuilding offering;



KEVIN T. COLLINS Partner

NEW YORK

Office: 212 891-1634

Email: kcollins@jenner.com

PRACTICE GROUPS

Corporate
Food and Beverage
Japan Practice
Mergers & Acquisitions
Private Equity
Securities

INDUSTRY GROUPS

Life Sciences

EDUCATION

Seton Hall University School of Law, J.D.,
1980

Fordham University, B.A., 1976

ADMISSIONS

New York, 1981

COURT ADMISSIONS

U.S. District Court, Southern District of New
York

- US Foods Holding Corp. (NYSE: USFD) in its \$1.175 billion initial public offering;
- US Foods Holding Corp (NYSE: USFD) in a \$1 billion secondary offering of common stock;
- Snyder's-Lance Inc. in its \$1.8 billion acquisition of Diamond Foods Inc. (Nasdaq:DMND);
- Clementia Pharmaceuticals (Nasdaq: CMTA) in its \$137.9 million initial public offering;
- NPS Pharmaceuticals in its \$100 million public offering of common stock;
- US Foods in its registered \$1.35 billion debt exchange offer;
- Clementia Pharmaceuticals in its \$60 million cross-over private placement;
- Swiss-based Lonza Group Ltd. in its agreement to acquire all of the outstanding shares of Arch Chemicals, Inc., for a purchase price of approximately \$1.2 billion;
- Bayer HealthCare AG in its collaboration agreement with Nuvelo for alfimeprase and its collaboration agreement with ZymoGenetics;
- Bayer HealthCare LLC in its license and collaboration agreement with Regeneron Pharmaceuticals for VEGF Trap;
- Tengion, Inc., a leader in the field of regenerative medicine, in its initial public offering and its Series C financing;
- Obagi Medical Products, Inc., in its initial public offering and its \$144.9 million follow-on public offering;
- Heartland Payment Systems, Inc., a credit card payment processor, in its initial public offering and its \$145 million follow-on public offering;
- Otsuka Pharmaceutical in its \$200 million acquisition of the Busulfex assets from PDL BioPharma and its acquisition of Interpharma Praha, a.s., a Czech Republic-based pharmaceutical manufacturer;
- Enzon Pharmaceuticals in its sale of a portion of its royalty interest for PEG- Intron;
- A.L. Industrier AS, the controlling shareholder of Alpharma, Inc., in its sale of its interest in Alpharma for \$305 million.

Awards

- *Law360 MVP*
Capital Markets, 2016
- *New York Metro Super Lawyers*
Mergers & Acquisitions, 2014-2017
Securities & Corporate Finance, 2015
- *Legal 500 US*
M&A/Corporate and Commercial - M&A: Middle-Market (\$500-\$999M), 2018